FDA ENFORCEMENT ACTIONS WOULD BE "SEVERELY" HINDERED BY PROPOSED GOP RISK ASSESSMENT REGS, AGENCY OFFICIAL CONTENDS BEFORE HOUSE HEARING ON HR 9
FDA compliance with proposed Republican risk assessment regulations would "severely impede" the agency's ability to initiate enforcement actions for drugs, medical devices and other products by imposing formal risk assessment requirements on what are currently informal decisions, FDA Deputy Commissioner for Policy Bill Schultz warned at a Feb. 2 hearing on Title III of the "Job Creation and Wage Enhancement Act" (HR 9). The hearing was held jointly by two House Commerce subcommittees: Health and Commerce & Trade.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth